IMPEDIMED LIMITED — AGM Information 2025

Nov 17, 2025

Annual General Mee+ng 18 November 2025

Chairs Address - Ms Chris+ne Emmanuel-Donnelly

Good morning and welcome to the 2025 Annual General Meeting of ImpediMed Limited. It is a privilege to address you as Chair.

First, I would like to acknowledge and thank the shareholders for trusting in us as a Board and management team to navigate and drive the long-term success of ImpediMed, and continue to serve and improve the lives of patients from preventable pain in the BCRL category as well as work towards further improved patient outcomes in the categories of Cardiac health, wellness and medical weight management. We have reinforced our position as a leader in the diagnosis and management of lymphoedema, and see increasing use of the SOZO device in assisting work flow management for surgeons and clinicians.

As a Board, we take very seriously our role in setting the strategic direction of the company, governance of the company’s risk, and of choosing and overseeing the excellent management team to drive the success of the company. On Board practice, I’d like to point out that Andrew Grant has now completed a year back on the Board following on from his six month role in the business back in the 2024 financial year, and we see him as a full Non-Executive Director for the 2026 year ahead and are confident in the majority independence of the Board.

The 2025 year saw payor coverage increase significantly in the second half of the 2025 financial year, with 26 states greater than 90% coverage. We expect to see more momentum in BCRL sales as a result. We saw a steady 23% revenue growth in 2025, and with pivoting investment towards our sales capability, we are confident in the commercial execution of the BCRL opportunity. This is continuing to grow, and the management team has made good decisions about recruitment in sales capability and continue to refine the sales process, with a number of staff also supporting the post sales process for increased SOZO utilisation.

The value proposition for the long term success of this business lies in the digital health platform and as much as we are excited about the increased momentum in BCRL, and be rest assured, we remain committed towards accelerating the success of this opportunity, we are also buoyed by the opportunity to cost effectively leverage the multiple technologies across the SOZO digital health platform, taking advantage of the commercial opportunities and progressing better patient outcomes across these categories.

The team has been working across various categories of the SOZO Digital Health Platform, preparing the path for commercial execution. As we have iterated previously, the SOZO device has multiple FDA cleared applications including FDA clearance for Lymphoedema, body composition, heart failure and protein calorie malnutrition. The Heart Failure category has a $1.1bn opportunity with the body composition category, at around $600M. The team is open to opportunities to expand into these categories in the most efficient way and are working on various options. As a Board we support exploring any opportunities which may become available to us, including new collaborations, potential mergers, distributors, and acquisitions in certain categories in order to ensure we realise the full value of the SOZO Digital health platform. Dr Parmjot Baines will describe these categories and the opportunities in more detail in her presentation.

I would like to thank my colleagues on the Board, not only do you bring your executive experience, but also your keen questioning and challenge to the Board and to management. I also thank our staff for their continuing passion, dedication and hard work. It has been difficult for the Board and management whilst we resize our costs, and we are confident these steps will contribute to the future success of the company.

Finally, and to reiterate our thanks to the shareholders for their continuing trust and support. We do not take this lightly and share your passion to make ImpediMed a success.

I will now pass to Dr Parmjot Baines for her presentation, and we will take questions after that.